OYST Stock Overview
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States.
Oyster Point Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.62|
|52 Week High||US$19.98|
|52 Week Low||US$3.46|
|1 Month Change||-10.51%|
|3 Month Change||27.15%|
|1 Year Change||-53.01%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-70.08%|
Recent News & Updates
Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
Oyster Point Pharma (NASDAQ:OYST) on Wednesday said its nasal spray Tyrvaya for the treatment of dry eye disease would now be covered by the largest Medicare pharmacy benefit manager (PBM) in the U.S. OYST did not name the PBM in its statement. Tyrvaya would be added by the PBM on its Medicare part D formularies, effective Sept. 1, OYST said. "In the United States, almost half of the total dry eye disease prescriptions are covered by Medicare...," OYST CEO Jeffrey Nau said. OYST in its Q2 earning report last week said Tyrvaya brought in net product revenue of $4.7M, and that there were about 30K Tyrvaya prescriptions filled during the quarter.
Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know
There's been a notable change in appetite for Oyster Point Pharma, Inc. ( NASDAQ:OYST ) shares in the week since its...
|OYST||US Biotechs||US Market|
Return vs Industry: OYST underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: OYST underperformed the US Market which returned -23.2% over the past year.
|OYST Average Weekly Movement||13.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: OYST is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: OYST's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company’s product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy.
Oyster Point Pharma Fundamentals Summary
|OYST fundamental statistics|
Is OYST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OYST income statement (TTM)|
|Cost of Revenue||US$3.17m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-5.87|
|Net Profit Margin||-493.39%|
How did OYST perform over the long term?See historical performance and comparison
Is OYST undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OYST?
Other financial metrics that can be useful for relative valuation.
|What is OYST's n/a Ratio?|
Price to Sales Ratio vs Peers
How does OYST's PS Ratio compare to its peers?
|OYST PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
MREO Mereo BioPharma Group
ARMP Armata Pharmaceuticals
URGN UroGen Pharma
ADCT ADC Therapeutics
OYST Oyster Point Pharma
Price-To-Sales vs Peers: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (9.5x).
Price to Earnings Ratio vs Industry
How does OYST's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is OYST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||4.7x|
|Fair PS Ratio||18.2x|
Price-To-Sales vs Fair Ratio: OYST is good value based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (18.2x).
Share Price vs Fair Value
What is the Fair Price of OYST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OYST ($5.62) is trading below our estimate of fair value ($263.78)
Significantly Below Fair Value: OYST is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Oyster Point Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OYST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OYST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OYST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OYST's revenue (51.2% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: OYST's revenue (51.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OYST's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Oyster Point Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OYST is currently unprofitable.
Growing Profit Margin: OYST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OYST is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.
Accelerating Growth: Unable to compare OYST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OYST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: OYST has a negative Return on Equity (-1462.35%), as it is currently unprofitable.
Discover strong past performing companies
How is Oyster Point Pharma's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OYST's short term assets ($132.7M) exceed its short term liabilities ($31.1M).
Long Term Liabilities: OYST's short term assets ($132.7M) exceed its long term liabilities ($102.0M).
Debt to Equity History and Analysis
Debt Level: OYST has more cash than its total debt.
Reducing Debt: Insufficient data to determine if OYST's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OYST has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OYST has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 48.5% each year.
Discover healthy companies
What is Oyster Point Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Oyster Point Pharma Dividend Yield vs Market|
|Company (Oyster Point Pharma)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Oyster Point Pharma)||n/a|
Notable Dividend: Unable to evaluate OYST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OYST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OYST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OYST's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OYST has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Nau (47 yo)
Dr. Jeffrey Nau, also known as Jeff, Ph. D, M. M. S, has been President, Chief Executive Officer and Director at Oyster Point Pharma, Inc since October 2017. Dr. Nau served as Vice President of Clinical an...
CEO Compensation Analysis
|Jeff Nau's Compensation vs Oyster Point Pharma Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$3m||US$563k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$6m||US$530k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$4m||US$390k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$390k||US$300k|
Compensation vs Market: Jeff's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
Experienced Management: OYST's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: OYST's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Oyster Point Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Oyster Point Pharma, Inc.
- Ticker: OYST
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$150.793m
- Shares outstanding: 26.83m
- Website: https://www.oysterpointrx.com
Number of Employees
- Oyster Point Pharma, Inc.
- 202 Carnegie Center
- Suite 109
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OYST||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/02 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.